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compiled. In order to determine a non-cytotoxic concen-
tration range, cytotoxicity data were obtained for all com-
pounds from HeK293 cells and from murine embryonic 
stem cells. moreover, an estimate of relevant exposures was 
provided by literature data mining. To evaluate feasibility 
of the suggested test framework, we selected a well-charac-
terized assay that evaluates ‘migration inhibition of neural 
crest cells.’ screening at the highest non-cytotoxic concen-
tration resulted in 11 hits (e.g., geldanamycin, abiraterone, 
gefitinib, chlorpromazine, cyproconazole, arsenite). These 
were confirmed in concentration–response studies. subse-
quent pharmacokinetic modeling indicated that triadimefon 
exerted its effects at concentrations relevant to the in vivo 
situation, and also interferon-β and polybrominated diphe-
nyl ether showed effects within the same order of magni-
tude of concentrations that may be reached in humans. In 
Abstract Developmental toxicity in vitro assays have 
hitherto been established as stand-alone systems, based on 
a limited number of toxicants. Within the embryonic stem 
cell-based novel alternative tests project, we developed a 
test battery framework that allows inclusion of any devel-
opmental toxicity assay and that explores the responses of 
such test systems to a wide range of drug-like compounds. 
We selected 28 compounds, including several biologics 
(e.g., erythropoietin), classical pharmaceuticals (e.g., roflu-
milast) and also six environmental toxicants. The chemical, 
toxicological and clinical data of this screen library were 
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conclusion, the test battery framework can identify com-
pounds that disturb processes relevant for human develop-
ment and therefore may represent developmental toxicants. 
The open structure of the strategy allows rich information 
to be generated on both the underlying library, and on any 
contributing assay.
Keywords Test battery-based compound screening · 
Developmental toxicity testing · hesC-based test system · 
neural crest migration assay
Abbreviations
ADme  Absorption, distribution, metabolism, excretion
bFGF  Basic fibroblast growth factor
BmC  Benchmark concentration
BmCL  Benchmark concentration 95 % confidential 
interval lower limit
CC  Clinical concentration
CCr  Chemokine receptors
Cns  Central nervous system
CsF  Cerebrospinal fluid
CyP  Cytochrome P450
Dll  Distal less
DnT  Developmental neurotoxicity
DT  Developmental toxicity
eGF  epidermal growth factor
esnATs  embryonic stem cell-based novel alternative 
tests
FCC  Free concentration
GD  Gestational day
HeK293  Human embryonic kidney 293 cell
hesC  Human embryonic stem cell
IFn-β  Interferon β
LOAeC  Lowest observed adverse effect concentration
meF  mouse embryonic fibroblast cell
mesCn  murine embryonic stem cell-derived neural 
precursor
mInC  migration of neural crest cell
mPP  matrix metalloproteinases
nCC  neural crest cell
nOAeL  no observed adverse effect level
PBDe  Polybrominated diphenyl ether
PBPK  Physiology-based pharmacokinetic
PCB  Polychlorinated biphenyl
rOI  region of interest
Introduction
Individual human embryonic stem cell-based developmen-
tal toxicity test systems have been established by several 
laboratories (Jagtap et al. 2011; Balmer et al. 2012; stum-
mann et al. 2009). A next step will be the combination of 
these and other assays to a comprehensive battery able 
to predict human developmental toxicities (Leist et al. 
2012b; van Thriel et al. 2012). Cultures of differentiat-
ing pluripotent stem cells such as human embryonic stem 
cells (hesC) or human-induced pluripotent stem cells 
(Leist et al. 2008a; Thomson et al. 1998; Takahashi et al. 
2007) offer unique possibilities of studying the very early 
steps of human development that lead to the formation of 
germ layers and primordial tissues. This opportunity was 
seized by the european Union research consortium for the 
use of ‘embryonic stem cell-based novel alternative tests’ 
(esnATs) for the prediction of toxicity of drug candidates 
(www.esnats.eu). This project focused on the one hand 
on transcriptomics-based toxicity predictions (Krug et al. 
2013b; Kuegler et al. 2010). On the other hand, several tests 
were established, which allowed the assessment of neuro-
chemical and cell biological cell functions (stiegler et al. 
2011; Zimmer et al. 2011b; 2012; Krug et al. 2013a) and 
of complex cell interactions (Preynat-seauve et al. 2009; 
Kuegler et al. 2012). moreover, concepts have been devel-
oped to compare relevant in vitro and in vivo concentra-
tions (Bosgra et al. 2012; Krug et al. 2013a; Zimmer et al. 
2011a), and to incorporate systems for metabolic activation 
of drugs (Godoy et al. 2013). It is assumed by many experts 
that the combination of such different tests in a battery may 
eventually be able to predict human developmental toxic-
ity (Basketter et al. 2012; Piersma et al. 2013; schenk et al. 
2010). The hesC-based test systems of esnATs cover 
different aspects of development. For instance, the UKK 
system (meganathan et al. 2012) models early multi-germ-
layer differentiation, while the UKn1 system (Balmer et al. 
2012) models specific neuroectodermal differentiation. The 
UKn2 system, also known as ‘migration inhibition of neu-
ral crest’ assay (mInC) (Zimmer et al. 2012) is a functional 
test probing the inhibition of neural crest cell migration by 
chemicals. During the initial establishment of the assays, 
only a small number of positive and negative controls were 
tested. Therefore, the applicability domain of these assays 
and their response dynamics when faced with a broader 
variety of compounds are unknown. moreover, the infor-
mation from only few compounds is not sufficient to evalu-
ate how far the test systems are complementary, and where 
they may be redundant in the information they provide.
In DnT test library selection, new approaches are 
required (Leist et al. 2012a) to break a vicious circle 
between lack of sufficient tool compounds, and the inabil-
ity to classically validate test systems without such com-
pounds (Leist et al. 2010, 2012b). One of these would be 
a screening approach of hitherto little characterized com-
pounds in multiple test systems. This would provide infor-
mation on which biological processes may be targeted by 
the compounds. Together with mechanistic studies on the 
mode of action, this approach may allow to build a case for 
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a hazard estimate independent of correlations with in vivo 
data (Kadereit et al. 2012). moreover, characterization of 
the available assays would be promoted.
For the design of such a battery of different tests, experi-
ence from earlier approaches can be used as guidance. Test 
batteries may for instance be constructed in a tiered way to 
avoid redundant testing. If information on each compound 
from every test is desired, then non-tiered approaches 
are more useful. examples from the field of reproductive 
toxicity testing are for instance the reProTect feasibility 
study (schenk et al. 2010) or the Chemscreen test battery 
(Piersma et al. 2013). non-tiered testing is also performed 
in the ToxCast Program, in which hundreds of tests have 
been run in parallel, to use the data afterward—in combina-
tion with pre-existing in vivo data—for predictions of driv-
ers and mechanisms of reproductive toxicity (Kleinstreuer 
et al. 2011; Padilla et al. 2012; sipes et al. 2011).
Here, we defined a framework for a test battery, and 
we provided an initial characterization of a core set of 
test compounds which can be expanded at later stages. 
To evaluate the feasibility of the suggested framework 
and the usefulness of the set of compounds, we selected 
one well-characterized assay for a first screen. The mInC 
assay (Zimmer et al. 2012) was selected, as it is based on 
a functional endpoint, and it affords sufficient throughput 
to evaluate a compound battery of that size. The underly-
ing biological rationale of the test is that disturbance of 
neural crest migration by toxicants leads to severe malfor-
mations in different species. several factors (e.g., genetics 
and chemicals) have already been identified as causes for 
neural crest (nC)-related developmental defects (Di renzo 
et al. 2007; Fuller et al. 2002; menegola et al. 2000). Iden-
tification of several hits in such a functional assay pro-
vides a good starting point for future characterization of 
the compounds by more phenotypic assays and for corre-




The reporter hes cell line H9-Dll1 (GFP under Dll1 pro-
moter) was provided by mark Tomishima from the memo-
rial sloan-Kettering Cancer Centre (msKCC, ny, UsA). 
Import of the cells and all experiments were carried out 
according to German legislation under the license number 
1710-79-1-4-27 of the robert-Koch Institute. H9-Dll1 cells 
were maintained on mouse embryonic Fibroblasts (meFs) 
in Dmem/F12 (Gibco) medium containing 20 % of serum 
replacement, HePes (1 m, Gibco), l-glutamine (Glu-
tamax, Gibco), non-essential amino acids (mem neAA, 
Gibco), beta-mercaptoethanol (Gibco) and basic fibroblast 
growth factor (10 ng/ml, Invitrogen). The murine es cell 
line CGr8 was obtained from the european Collection of 
Cell Culture (eCACC, UK). CGr8 cells were maintained 
on 0.1 % gelatin-coated dishes in BHK21 medium, sup-
plemented with 10 % fetal calf serum, l-glutamine, non-
essential amino acids, penicillin/streptomycin and leukemia 
inhibitory factor (Kern et al. 2013). HeK293 (CrL-1573, 
ATCC) cell line was maintained in Dmem supplemented 
with 10 % fetal calf serum at 37 °C in a humidified atmos-
phere containing 5 % CO2.
neural differentiation protocols
The mesC cell line (CGr8) was differentiated toward a 
neural stem cell phenotype using the protocol described 
by Barberi et al. (2003). Briefly, CGr8 were seeded on 
irradiated ms5 cells and cultivated in Dmem medium 
containing 15 % Knock-out serum replacement, non-
essential amino acids, beta-mercaptoethanol and penicillin/
streptomycin. After 4 days, cells were replated on polyor-
nithine (15 μg/ml)-coated dishes in n2 medium contain-
ing Dmem, n2 supplement, penicillin/streptomycin and 
10 ng/ml of basic human fibroblast growth factor (Invit-
rogen). Differentiation of hesC into neural crest cells was 
initiated on mitomycin C-treated murine bone marrow-
derived stromal ms5 cell line and continued as described 
in Zimmer et al. (2012).
evaluation of a non-cytotoxic range by resazurin assay 
and benchmark concentration (BmC) calculation
The effects of the toxic compounds on cell viability of two 
cell lines were evaluated by using the resazurin assay. The 
assay is based on the capability of viable and healthy cells 
to reduce resazurin to resorufin, which can be measured 
by a colorimetric or fluorimetric shift as described earlier 
(Zimmer et al. 2012). HeK293 cells and mesC-derived 
neural stem cells (mesCn) were exposed for 48 h to the 
different substances. mesCn were exposed to test com-
pounds after 6 days of differentiation. After this period, the 
cells were incubated at 37 °C and 5 % CO2 with 10 μg/ml 
resazurin for 30 min (HeK293) or up to 5 h (neural stem 
cells). The background fluorescence of resazurin itself was 
determined by including a resazurin only control. resa-
zurin reduction was analyzed in cell culture medium fluori-
metrically (λex = 530 nm, λem = 590 nm). These data were 
used to model a concentration–response curve and to calcu-
late the concentration corresponding to a 10 % reduction in 
viability (BmC10). In addition, the BmC15 and the lower 
limit of its 95 % CI (BmCL15) were determined. This lat-
ter value was used as estimate for the upper boundary of 
the non-cytotoxic concentration range.
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Cell migration analysis
Cell migration analysis was carried out using a scratch assay 
design as described in Lee et al. (2009) and Zimmer et al. 
(2012) with minor modifications. hesC-derived nCCs were 
grown to a confluent monolayer using 48-well plates (Corn-
ing). right before starting the assay, each well was scratched 
using a 20-μl pipette tip in order to create a cell-free gap. The 
medium was removed and replaced by fresh medium con-
taining the test chemicals. The width of the cell-free gap was 
determined right after scratching in a control plate in order to 
define the dimension of the region of interest (rOI) for the 
analysis. The cells were exposed to the toxicants for 48 h; 
after this period, the general cytotoxicity was assessed by the 
resazurin reduction assay. migration of nCC was evaluated 
by florescence microscopy analysis. In order to easily count 
the number of cells, incubation with fresh medium containing 
the DnA dye H-33342 (1 μg/ml) was performed for 30 min. 
After the incubation period, random images along the scratch 
were taken at 4× magnification. The number of cells with 
H-33342-positive nuclei within the rOI was automatically 
calculated by the use of a KnIme flowchart.
Chemical exposure during migration
hesC-derived neural crest cells were exposed to chemicals 
in n2 medium containing eGF (20 ng/ml) and FGF2 (20 ng/
ml). For a detailed list of chemicals and their tested concen-
tration range used in this study, see Fig. 3 and Fig. s1, s2.
In vitro: in vivo comparison of toxicity data by PBPK 
modeling
In order to evaluate the clinical relevance of the in vitro 
concentrations found to impair the migration of the hesC-
derived nCCs in this study, a three-step (physiology-based) 
pharmacokinetic (PBPK) modeling strategy has been used, 
as already described in Krug et al. (2013b) and Piersma et al. 
(2013). Briefly, the following steps were taken: (a) choice 
of an appropriate absorption, distribution, metabolism, 
excretion (ADme) model; (b) use of this model to simu-
late plasma and/or target tissue concentrations in time cor-
responding to the exposure (dose, route of administration, 
interval) at which relevant toxic effects were observed in 
already published in vivo studies; (c) calculation of the nom-
inal concentration in vitro that has the same unbound con-
centration as the toxic concentration in vivo (when possible).
In vitro: in vivo comparison of toxicity data for interferon 
β
A PBPK model for the analysis of interferon β (IFn-β) 
kinetics in monkeys, described by mager et al. (2003), 
was implemented in the acslX software (version 3.0.2.1, 
Aegis Technologies) (step a). The original model was 
built on the basis of data from 18 cynomolgus monkeys 
that were exposed i.v. to single doses of 1, 3, 10 mIU/
kg and then to a s.c dose of 0.3 ml/kg of IFn-β. In vivo 
developmental toxicity concentrations of the drug have 
been extrapolated from a study reporting the effects of 





In vitro: in vivo comparison of toxicity data for triadimefon
A PBPK model for the pesticide triadimefon and its 
metabolite triadimenol in rats published by Crowell et al. 
(2011) was reconstructed in acslX and used to predict 
the target tissue concentration related to the exposure 
scenarios leading to toxic effects on male fertility and 
Cns toxicity (step a). Developmental toxicity-inducing 
concentrations were extrapolated from the in vivo study 
by Goetz et al. (2007), in which pregnant rats have been 
exposed to the pesticide. Two exposure scenarios were 
simulated: Dietary exposure assuming a constant intake 
of the entire drug dose within the first 12 h of 24-h peri-
ods; oral gavage, modeled as a bolus dose into the liver 
compartment (step b). The nominal in vitro concentra-
tions equivalent to the concentrations predicted in vivo 
were determined correcting for the differences in albu-
min concentration and lipid fraction between plasma or 
cerebrospinal fluid and test medium, using the follow 
equations:
where eC represents the effective concentration; fb,p the 
plasma fraction unbound; Kow the octanol:water parti-
tion coefficient; vFL the lipid fraction; P the albumin 
concentration; suffix u means unbound; suffix p the 
plasma; and suffix x the other medium (in vitro or CsF) 
(step c).
The parameters of free (unbound) fraction, 
octanol:water partition and blood:plasma concentra-
tion ratio were taken from the published study by (Us 
ePA 2006) and 0.11, 912 and 0.84, respectively. Data for 
rat CsF (estimated as 0.5 % of plasma) were taken from 
(Habgood et al. 1992; Koch et al. 2001) and data for 
mInC culture medium were calculated based on informa-
tion provided by the supplier.
ECx = ECp ×
{
(1 − fb,p) ×
1 + Kow × VFL,x






ECx − PxPp × fb,p × ECp
1 + Kow × VFL,x
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In vitro: in vivo comparison of toxicity data for PBDE‑99
A PBPK model was constructed based on data of tis-
sue distribution, metabolism and excretion of PBDe-
99 as described by Hakk et al. (2002) and Chen et al. 
(2006) (step a). The PBPK model structure to describe 
the kinetics of PBDe-99 is shown in Fig. s4a. The 
model contains a gastrointestinal lumen compartment 
(GI), two rapid equilibrium compartments (T1 and T2), 
a blood compartment (B), a lipophilic tissues compart-
ment (F) representing adipose tissue and skin, and com-
partments for urinary and fecal excretion (Ur and Fe). 
The exchange between blood and tissue compartments 
is described by first-order rate constants kb1, k1b, kb2, 
k2b, kbf and kfb with unit h−1. The compound is absorbed 
into T1—containing intestinal tissues and liver, but not 
further specified—by a rate kab, and eliminated back 
into GI with rate kel. excretion occurs from the blood 
compartment with rate kur and from the GI compart-
ment with rate kfe. The model was described as a set 
of differential equations in acslX. Concentrations were 
calculated from amounts by dividing compartment vol-
umes: 0.21, 0.56 and 0.06 ml/g BW (body weight) for 
lipophilic tissues, rapid equilibrium tissues and blood, 
respectively, as reported by Brown et al. (1997). The 
estimated parameter values are listed in the supplemen-
tal material (Fig. s3b). The model performance was 
demonstrated by comparison of model predictions to in 
vivo PK data reported by Chen et al. (2006) for a sin-
gle oral dose of 1 μmol/kg (Fig. s3 c,d) and an intra-
venous bolus dose of 1 μmol/kg (Fig. s3e, f). In vivo 
developmental toxicity concentrations were extrapolated 
by the data from Kuriyama et al. (2005) and viberg et al. 
(2005), where neuro-developmental effects are observed 
in rats exposed to PBDe-99, during the gestational or 
the early infancy period (step b).
statistics and data mining
For the resazurin assay, five technical replicates for 
HeK293 cells and four biological replicates for mesCn 
cells have been analyzed for each compound and concen-
tration. For the migration assay, the number of migrated 
cells was automatically counted in ≥4 different images 
per experiment by a KnIme flowchart-based software. 
All data displayed are means from three independent bio-
logical experiments. each biological experiment consisted 
of at least four technical replicates. statistical differences 
were tested with GraphPad Prism 5.0 (Graphpad software, 
La Jolla, UsA) by applying AnOvA using Bonferroni’s 
post hoc test. Independent biological experiments (not 
technical replicates) were the basic unit used for statistical 
testing.
Results
Considerations and design principles of the test battery
several murine and human stem cell-based developmental 
toxicity test systems have been developed by esnATs pro-
ject partners (Balmer et al. 2012; Krug et al. 2013b; stie-
gler et al. 2011; Zimmer et al. 2012; Kern et al. 2013; Jag-
tap et al. 2011) and others (Fritsche et al. 2011; seiler and 
spielmann 2011; Hogberg et al. 2010; Pallocca et al. 2013; 
Piersma et al. 2013; suzuki et al. 2011). All these assays 
have been evaluated individually with positive and negative 
control compounds regarding their biological relevance for 
fundamental processes of mammalian development. How-
ever, little is known how such test systems can be com-
bined to yield information on drug toxicity.
Important features of the test battery framework are 
the characterization of the compounds concerning general 
cytotoxicity, relevant in vivo concentrations and other nec-
essary background data. Accessory modules for hit follow-
up and in vitro–in vivo extrapolation should provide rich 
information on many of the compounds in the future. In 
fact, one of the initial purposes of the test battery was the 
pre-filtering of hits for further toxicogenomics follow-up, 
for instance by transcriptome profiling (Figs. 1, 2a). This 
will be performed, once a sufficient number of hits will be 
characterized in different assays.
selection of test battery compounds
The 28 compounds were compiled according to the selec-
tion criteria outlined in Fig. 2b. The test library reflects a 
compromise between the different criteria. Our choice 
marks a deliberate and intentional departure from the 
use of known toxicants and endpoint-specific controls 
(reviewed in Kadereit et al. 2012; Crofton et al. 2011; Leist 
et al. 2010), and it puts emphasis on the exploration of 
unknown drugs. Besides the drugs, a small selection (six 
substances) of environmental pollutants (e.g., PCB, PBDe, 
arsenic) was included as likely positive controls for many 
test systems. The group of drugs also included biolog-
ics (e.g., interferon-β, oxytocin) and peptide-related small 
molecules (e.g., sitagliptin, galnon). some of the biologics 
were included as they are known to cross the blood brain 
barrier in vivo (e.g., G-CsF, erythropoietin). Finally, three 
compounds (sulfadiazine, chlorpromazine, amiodarone) 
were chosen because another drug screen (Kern et al. 2013) 
suggested a potential for developmental neurotoxicity. For 
all compounds of the test library, essential chemical and 
pharmacological information was compiled (Fig. s1, s2; 
Fig. 3). For environmental compounds with known neuro-
toxicity (developmental neurotoxicity) we referred to sev-
eral pertinent in vivo and in vitro studies.
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Pre-screening of test battery compounds for general 
cytotoxicity
most developmental neurotoxicity assays give reliable and 
specific results only when compounds are used at concen-
trations that do not trigger general cytotoxicity/cell death. 
This range has to be determined for each compound and 
each test system. However, most available assays allow 
only a relatively low throughput of samples. Therefore, it 
would be more efficient and economical to get some rough 
initial information on non-cytotoxic concentration ranges 
before the onset of testing. For this purpose, we used two 
different assays. The first was based on human HeK293 
cells. resazurin reduction was applied as viability endpoint 
after exposure to the test battery compounds for 48 h. The 
second assay made use of mesCn differentiated toward 
neural lineage. Also here, viability of the cells was deter-
mined by resazurin reduction after a 48 h exposure period 
during the initial stages of differentiation (starting on day 
6). The combination of these assays was meant to cover 
many modes-of-action of cytotoxicants across species and 
cell biological functions.
To determine the non-cytotoxic concentration range, 
compounds were tested at multiple concentrations. We then 
used a mathematical procedure to determine a benchmark 
concentration as upper limit of the non-cytotoxic range. 
The procedure is displayed in detail for the example com-
pound geldanamycin (Fig. 4). For practical purposes, we 
used the real data point closest to this calculated theoreti-
cal threshold as toxicity threshold (Fig. 3). In most cases 
(16 compounds) in which comparative data were avail-
able, minimum cytotoxic concentrations of the compounds 
for the two cell types were similar (<5-fold difference). 
For all remaining substances (8 compounds), the embry-
onic stem cell system showed a higher sensitivity than the 
HeK293 cell line (Fig. 3). Cytokines were only tested at 
Fig. 1  Overview of the esnATs test battery. Candidate compounds 
were compiled based on criteria described in Fig. 2, and a final set 
of 28 drugs and environmental pollutants was selected. Their charac-
teristics, including compound source, solubility, clinical concentra-
tion ranges and toxicological background information were compiled. 
Two approaches were chosen to determine a non-cytotoxic range for 
the further screening: cytotoxicity pre-screening on a transformed 
cell line derived from human embryonic kidney (HeK293) and on 
murine embryonic stem cell-derived differentiating neural cells 
(mesCn). In addition, realistic exposure concentrations were esti-
mated from literature data mining (for in vitro toxicity information) 
and pharmacokinetic (PK) prediction (free plasma concentrations). 
The test battery comprised initially the UKn2 test system and three 
other hesC-based tests, but it was designed openly for any test addi-
tion. screening proceeded in two steps: first the highest non-toxic or 
relevant concentration for a given test was determined; then com-
pounds were tested in hesC models at this concentration. Based on 
the results of the screening, a shortlist of compounds was selected for 
further characterization by physiologically based pharmacokinetics 
(PBPK) modeling and for hit follow-up
Fig. 2  Test battery design criteria
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pharmacological concentrations to be expected in body 
fluids, and they all proved to be non-cytotoxic at these test 
concentrations (Fig. 3). In summary, the viability data give 
a rough indication on good starting points, but more precise 
data are needed for each new experimental model and for 
each experimental variation within a given test system (see 
below).
Determination of toxicologically relevant concentration 
ranges
Besides non-cytotoxicity, further criteria are important 
to determine reasonable test concentrations and to inter-
pret the data. To allow decisions on concentration ranges 
(e.g., for cytokines) and interpretation of screen results, we 
compiled the clinical blood and tissue concentrations (CC) 
for most compounds. These, together with data on plasma 
protein binding, were used to calculate the free plasma 
concentrations in patients. The latter data are important to 
relate in vivo data to in vitro concentrations. While an over-
view of the data is given in Fig. 3, more detailed informa-
tion has been compiled in a supplementary table (Fig. s4).
For extrapolation of in vivo data to in vitro concentra-
tions, often the issue arises, whether Cmax (the peak concen-
tration reached in clinics) or AUC (the average concentra-
tion found in a patient) should be used as anchor point for 
calculations. In the present study, both plasma peak (Cmax) 
and average data were considered. This allows case-by-case 
decisions, depending on the assumed mechanism of toxic-
ity. For instance, it may be plausible that cytokine receptors 
need to be triggered only for a short time (by Cmax) to gen-
erate intracellular signals that potentially affect differentia-
tion. In contrast to this situation, continuous cytokine signal-
ing (in the AUC range) may be required to alter the cellular 
Fig. 3  Toxicological background data for all compounds screened 
in the test battery. The solvent used for each compound is indicated. 
Data on clinical concentrations (maximal plasma concentration) 
and the free plasma concentrations are explained in greater detail in 
supplementary Fig. s4. The data obtained from the cytotoxicity pre-
screening in HeK293 and mesCn cells are reported as the real data 
points closest to the mathematically modeled highest non-cytotoxic 
concentrations (BmCL15). The highest non-cytotoxic concentra-
tion determined in the UKn2 test system is also indicated. The last 
column indicates the lowest observed adverse effect concentration 
(LOAeC), the concentration triggering a 20 % inhibition of migration 
of the neural crest cells. (n.a. not available data, n.t. not tested)
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cytoskeleton and thereby to affect the cellular migration 
capacity. vice versa, an environmental toxicant that inhib-
its a cellular pathway may need to do this continuously to 
exert developmental effects, i.e., an average toxic concentra-
tion (AUC) needs to be maintained to result in an average 
long-term inhibition. A short pulse, even at Cmax may not 
be toxic. However, the situation would be different, if the 
compound (such as arsenite) binds irreversibly to cellular 
structures above a certain threshold concentration. Under 
such circumstances, the Cmax values would become relevant.
Inhibition of neural crest cell migration by test battery 
library
As first assay to be run within the framework of the test bat-
tery, we chose the UKn2 test system that evaluates inter-
ference of potential toxicants with neural crest (nC) cell 
migration (Zimmer et al. 2012). For the primary screen, the 
library was run at a single concentration, selected accord-
ing to the cytotoxicity pre-screening. At this concentration 
the viability of nCC was determined. If the concentration 
was non-toxic for nCC, then inhibition of migration was 
determined in the mInC assay. If the compounds were ini-
tially toxic, the UKn2 toxicity threshold was determined 
and then the mInC assay was performed at this concen-
tration. When comparing cytotoxicity tests across differ-
ent cell lines and models, we observed that cytotoxicity 
depends not only on the cell type and the medium used. 
Often minor experimental details affected the outcome 
(e.g., the plate type used). Therefore, the most relevant cell 
viability data were obtained when this endpoint was meas-
ured in each test run, and directly within the sample used 
for measuring the specific endpoint (e.g., migration). For 
instance, about two-thirds of the test compounds showed 
similar cytotoxicity thresholds in the pretesting models 
(HeK293; mesCn) and the mInC. For two compounds, 
cytotoxicity of the nCC resembled rather the mesC than 
HeK293; for three other compounds, nCC sensitivity was 
closer to that of HeK293. After identification of adequate 
concentrations viability and mInC data were obtained for 
each compound, and experiments were repeated at this test 
concentration with two further cell preparations (Figs. 5, 
6). Hit compounds (Fig. 5) reduced the migration for at 
least 25 %, while they reduced cell viability in the same 
assay for <10 %. non-hits did either not affect migration 
strongly, or they influenced migration only above the cyto-
toxicity threshold (Fig. 6). Altogether 11 hits were identi-
fied, 5 of which came from the group of drugs. Within the 
latter group, the hit rate was 23 %; among the environmen-
tal compounds, the hit rate was 100 %.
Determination of the minimal concentration triggering 
developmental toxicity
To follow up on the hits from the initial screen by the 
mInC assay, a broader range of concentrations of these 
Fig. 4  Determination of the highest non-cytotoxic concentration. 
Compounds were tested at multiple concentrations, and cell viability 
was determined by the resazurin assay (every replicate is represented 
by a single circle, different color code for independent experiments). 
These data were used to model a concentration–response curve and 
the concentration corresponding to a 10 % reduction in viability 
(BmC10) was calculated (solid line). In addition, the BmC15 was 
determined and the lower limit of its 95 % CI (BmCL15, dashed line) 
was determined. This latter value was used as estimate for the upper 
boundary of the non-cytotoxic concentration range. An example of 
BmC determination for the compound geldanamycin is shown, using 
data obtained from the cytotoxicity pre-screening in a HeK-293 cells 
and b mesC-derived differentiating neural cells (mesCn)
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Fig. 5  Overview of hits identi-
fied in the UKn2 test system. 
neural crest cells were exposed 
to the highest non-cytotoxic 
concentration of test compounds 
for 48 h. The inhibition of cell 
migration and cytotoxicity 
induced by different com-
pounds were measured by a the 
mInC and b resazurin assays. 
substances leading to ≥25 % 
reduction in the nCC migra-
tion activity in the presence of 
≤10 % cytotoxicity (compared 
with the untreated controls) 
were considered UKn2-positive 
hits. Data are mean ± sD 
of three independent experi-
ments normalized to untreated 
controls. *p < 0.05, **p < 0.01, 
***p < 0.001
Fig. 6  Overview of negative compounds in the UKn2 test sys-
tem. The results of a 48 h exposure of neural crest cells to the high-
est non-cytotoxic concentration of test compounds are shown. The 
inhibition of cell migration and cytotoxicity induced by different 
compounds were measured by a the mInC and b resazurin assays. 
substances showing reduction in cell viability (>10 %) and/or reduc-
tion in migration <25 % (compared with the control) were considered 
UKn2-negative compounds. Data are mean ± sD of three inde-
pendent experiments normalized to untreated controls. *p < 0.05, 
**p < 0.01, ***p < 0.001
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compounds was tested in the same assay. We used these 
data to determine the lowest concentration inhibiting the 
specific test endpoint—neural crest cell migration. A non-
linear regression was fitted to the concentration–effect 
curve (Figs. 7, 8). For this type of follow-up assay, we 
assumed that a reduction in migration by 20 % was of bio-
logical and toxicological significance. The concentration 
triggering this extent of inhibition was determined and 
defined here as the ‘lowest observed adverse effect concen-
tration’ (LOAeC). This value represents the lowest concen-
tration at which inhibition of migration would become toxi-
cologically relevant in our test system (Fig. 3).
examples of PBPK modeling for hit compounds to relate 
in vitro correlations to realistic exposure scenarios
We selected three compounds for more detailed compari-
sons of LOAeC values and toxicologically relevant in vivo 
concentrations. First, recombinant human IFn-β was exam-
ined. A PBPK model for the analysis of IFn-β kinetics in 
monkeys has been described by mager et al. (2003). In this 
study, IFn-β plasma concentrations were measured during 
a period of 48 h in order to determine the pharmacokinetic 
and pharmacodynamic parameters necessary for modeling. 
The model of mager et al. (2003) postulates a decrease in 
receptor density upon repeated exposure to IFn-β, and an 
elimination of IFn-β (internalized into cells) depending 
on the receptor density. We implemented this PK model 
in the acslX software, and we simulated the kinetics of 
IFn-β after exposure to a dose known to trigger develop-
mental toxicity in animals: this simulated toxic dose was 
chosen based on an unpublished report summarized by 
the Us FDA (see materials and methods). In this report, 
developmental toxicity in pregnant monkeys exposed to 
IFn-β was shown for a dose of 740 ng/kg/day (= 33 pmol/
kg/day, assuming a molecular weight of 22.5 kDa) given 
from gestational day 90 to term (GD160). Our simulations 
showed for a subcutaneous dose of 33 pmol IFn-β/kg/day 
that receptor density decreased by about one-third. As a 
consequence, daily average plasma concentrations of IFn-β 
Fig. 7  Concentration-response curves for UKn2-positive environ-
mental pollutants. neural crest cells were exposed to different con-
centrations of each test compound for a period of 48 h. The inhibi-
tion of cell migration (red squares, solid line) and cytotoxicity (black 
dots) induced by different compounds were measured by the mInC 
and resazurin assays. a As2O3, b triadimefon, c PBDe-99, d cypro-
conazole and e PCB153 showed a concentration-dependent effect 
on the nCC migration, in a not-cytotoxic concentration range. Data 
are mean ± sD of three independent experiments normalized to 
untreated controls. *p < 0.05, **p < 0.01, ***p < 0.001 (color figure 
online)
▸
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increased from 0.9 to 1.5 pm. The simulated plasma peak 
concentrations were in the range of 2–3 pm (Fig. 8e). This 
value was about tenfold lower than our in vitro nOAeL (no 
observed adverse effects level), i.e., still within the same 
order of magnitude.
Triadimefon was the second compound selected for PK 
modeling because it represents a specific nCC toxicant 
(Zimmer et al. 2012; menegola et al. 2005). Further knowl-
edge on the mechanisms of toxicity would be of high inter-
est. We revisited/reconstructed the PBPK model by Crow-
ell et al. (2011) to predict the target tissue concentrations 
related to the exposure scenarios leading to published toxic 
effects on male fertility and the Cns (Goetz et al. 2007; 
Crofton et al. 2011), i.e., a dose of 50 mg/kg triadime-
fon. The maximum simulated total in vivo concentration 
(Cmax) and its average in the 24-h period (C24h) in plasma 
and brain were used as relevant exposure metrics. equal 
contribution of triadimefon and its metabolite triadimenol 
to the observed effects relative to their concentrations was 
assumed; therefore, the concentrations of both compounds 
were added. The obtained in vivo total concentration val-
ues were used in order to assess the equivalent in vitro con-
centrations (Fig. 9a). We simulated two scenarios: dietary 
exposure assuming a constant intake of the entire drug dose 
within the first 12 h of a 24-h period (Fig. 9b,c); oral gav-
age, modeled as a bolus dose into the liver compartment 
(Fig. 9d,e). The averaged C24h simulated in vivo in plasma 
after dietary exposure was estimated to be 18 μm, with a 
Cmax of 32 μm. C24h and Cmax in CsF were accordingly 15 
and 27 μm. Based on the parameters listed in Fig. 9a and 
on the equations reported in materials and methods, we 
calculated the free concentration in vivo and the equivalent 
total concentration in vitro (about 1 μm in plasma, and 18–
33 μm in CsF) (Fig. 9b). The same approach was used for 
the second analyzed scenario. A single dose of 50 mg/kg 
of triadimefon administrated by gavage was simulated in 
our model. The equivalent in vitro concentrations were 17–
196 μm (Fig. 9d). This illustrates that in vivo plasma con-
centrations were within the range of the mInC nOAeL.
Fig. 8  Concentration-response curves for drugs identified as hits in 
the UKn2 test system. neural crest cells were exposed to various 
concentrations of test compounds for a period of 48 h. The inhibi-
tion of cell migration (red squares, solid line) and cytotoxicity (black 
dots) induced by different compounds were measured by the mInC 
and resazurin assays. a Gleevec, b geldanamycin, c abiraterone and 
d interferon β (IFn-β) showed a concentration-dependent effect on 
the nCC migration, in a non-cytotoxic concentration range. Data 
are mean ± sD of three independent experiments normalized to 
untreated controls. (*p < 0.05, **p < 0.01, ***p < 0.001). e simula-
tion of IFn-β plasma concentration induced by a sub-cutaneous dose 
of 33 pmol/kg/day from GD90 (gestation day 90) to term (GD160) 
in cynomolgus monkeys, using a PBPK model published by mager 
et al. (2003) and reconstructed in acslX software (color figure online)
▸
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The third compound studied was PBDe-99. A new 
PBPK model was established for this purpose (Fig. s3). 
It was used to simulate concentrations in the rapid equi-
librium compartment (e.g., plasma) corresponding to 
the lowest exposures related to neurodevelopmental 
toxicity described in Kuriyama et al. (2005) and viberg 
et al. (2005). An oral dose of 0.11 μmol/kg (on gestational 
day 6, as used in the first study) was simulated to lead to 
a maximum concentration of 0.1 μm in our model (Fig. 
s5a). An oral dose of 1.4 μmol/kg (on postnatal day 10, 
Fig. 9  PBPK modeling of the pesticide triadimefon a The values of 
lipid fractions and albumin concentrations in rat plasma, cerebrospi-
nal fluid (CsF) and in vitro cell culture medium used to calculate the 
equivalent in vitro concentrations are listed. b–e The toxicokinetic 
behavior of triadimefon and its metabolite triadimenol was simu-
lated by using a PBPK model published by Crowell et al. (2011). 
Two different exposure scenarios are shown: b, c a dietary expo-
sure of 50 mg/kg triadimefon (intake for the first 12 h within a 24 h 
period) and d, e a single dose of 50 mg/kg triadimefon administered 
by gavage. b The maximum concentrations (Cmax) and the average 
concentrations (C24h) calculated for plasma and CsF are indicated for 
the first scenario: these values together with data in a were used to 
calculate the free concentration in vivo and the equivalent total con-
centration in vitro. c The simulated concentration of triadimefon and 
triadimenol in rat blood and brain compartment over time is shown 
for an oral dose of 50 mg/kg taken in the diet during the first 12 h of 
a 24 h period. d The maximum concentrations (Cmax) and the average 
concentrations (C24h) calculated for plasma and CsF are indicated for 
the second scenario: these values together with data in a were used to 
calculate the free concentration in vivo and the equivalent total con-
centration in vitro. e The simulated concentration of triadimefon and 
triadimenol in rat blood and brain compartment over time is shown 
for a single dose of 50 mg/kg
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as used by viberg et al. 2005) led to a simulated maximum 
concentration of 1.3 μm, with an average concentration of 
0.82 μm over the first 10 days after exposure (Fig. s5a). 
These concentrations were within the same order of magni-
tude as the mInC nOAeL.
Discussion
In the present study, we defined the framework for an in 
vitro developmental toxicity test battery. Although it was 
originally designed for assay systems that have been devel-
oped by the esnATs consortium (Leist et al. 2013), it may 
be expanded by any other robust test. Additionally, we per-
formed a feasibility study. For this, we chose the mInC 
assay (Zimmer et al. 2012), because its throughput and its 
functional endpoint allowed us to judge the suitability of 
the test strategy and compound library within a reason-
able time frame. The environmental chemicals with known 
DnT hazard potential that were included into the screen 
were all identified as hits. This confirmed the very high 
sensitivity of the assay. more importantly, new hits were 
identified among the group of medical drugs. This points to 
the usefulness of the test battery to provide safety informa-
tion on hitherto non-characterized drugs or environmental 
compounds.
The field of developmental neurotoxicity relies on only 
a handful of generally accepted positive controls, such as 
mercury, lead and pesticides (Grandjean and Landrigan 
2006; Kuegler et al. 2010; Kadereit et al. 2012). This situ-
ation is due to a lack of comprehensive human epidemio-
logical data as well as a dearth of DnT guideline studies on 
animals (rovida et al. 2011; makris et al. 2009; van Thriel 
et al. 2012). Therefore, instead of solely relying on the com-
pounds that have been used in the past, we applied a new 
approach by combining well-known positive controls with 
new compounds mainly belonging to the group of medi-
cal drugs. The test battery approach gives the opportunity 
to qualify this new group of compounds by non-tiered test-
ing in multiple assays covering different key biological 
processes. We envisage that this approach will yield some 
extremely well-characterized drug compounds, which could 
then be used in the future to increase the list of positive 
controls for in vitro assays. moreover, performance of the 
assays would be characterized by their hit patterns and by 
mechanistic studies on the hits in the respective test systems.
Although we acknowledge that our approach has weak-
nesses concerning the definition of positive controls, it pro-
vides nevertheless a new opportunity for breaking a vicious 
circle between lack of sufficient reference compounds and 
a paucity of validated assays. We feel that this strategy is 
worth being explored considering also that this approach 
has been successful in other fields. For instance, the area 
of chemically induced carcinogenesis faces similar prob-
lems, despite more than 1,000 times larger research efforts. 
The list of IArC (International Agency for research on 
Cancer) group 1 compounds (definite human carcinogens) 
contains only about four dozen chemicals. Considering 
the heterogeneity of cancer, this number is far too low to 
validate any assay by conventional correlative statistics. 
nevertheless, many assays have been developed, and many 
chemicals have been classified as potential carcinogens. 
This was done by recurrent optimization cycles involving 
testing of compounds, assay optimization, and adaptation 
of interpretation models. Human data are hard to obtain 
for chemically induced carcinogenesis, but some key bio-
logical processes responsible for human carcinogenesis, 
such as mutagenesis, promotion of growth, loss of contact 
inhibition can be defined and tested individually in vitro 
(Adler et al. 2011). This procedure and experience may be 
transferred to the field of DnT. We therefore believe that 
increasing the size and heterogeneity of the test compound 
library as well as comparing the toxicity data obtained in 
several assays for key biological processes will be a suc-
cessful strategy to overcome the lack of positive controls 
for DnT/DT.
By adding the new group of medical drugs to the test 
battery library, we also addressed a further issue: applica-
bility domains of most existing assays are poorly defined. 
The currently available test systems have been character-
ized by the use of well-known positive control compounds, 
which mainly belong to the group of environmental toxi-
cants (Klaric et al. 2013; vojnits et al. 2012; Krug et al. 
2013a; Pallocca et al. 2013; Laurenza et al. 2013; Piersma 
et al. 2013; Bal-Price et al. 2012; Crofton et al. 2011; 
Coecke et al. 2007; Lein et al. 2007; Kadereit et al. 2012). 
some others have used at most one to three drug-like com-
pounds (Balmer et al. 2012; stiegler et al. 2011; Kuegler 
et al. 2012; meganathan et al. 2012; Jagtap et al. 2011; Fal-
sig et al. 2004). Therefore, it is not clear whether these test 
systems are able to predict DT of drugs or specific groups 
of environmental compounds. Apart from two screening 
assays developed in the context of esnATs (Kern et al. 
2013; Krug et al. 2013a) the published assays have never 
been challenged by a broad range of drugs, and they may 
therefore not have been optimized to detect their adverse 
effects. However, the pharmaceutical industry would need 
such new assays capable to predict human DT in a more 
reliable fashion than the currently available tests. In the 
past years, pharmaceutical companies have struggled more 
and more to develop new drugs, while at the same time 
drugs already on the market had to be withdrawn due to 
safety issues. Between 1999 and 2011, 19 % of 279 newly 
approved drugs in europe were reported to have post-
approval safety issues and five drugs had to be withdrawn 
from the market (mol et al. 2013).
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The strategy used here also attempts to provide a new 
perspective on how the field of in vitro DT testing may 
advance with regards to future validation of assay systems. 
The classical situation foresees the comparison of in vitro 
toxic concentrations with the known in vivo toxic doses, 
as major indication of biological relevance. This approach 
is not suitable for developmental toxicity testing since not 
enough animal data are available. As alternative, a mecha-
nistic validation has been proposed (Leist et al. 2008b, 
2012b; Hartung et al. 2013). This concept is based on the 
assumption that toxicants disrupt key biological processes, 
and that test systems identify compounds that disrupt such 
processes (Leist et al. 2010; Crofton et al. 2011; Kadereit 
et al. 2012). For instance, cell migration represents such a 
key process (Fritsche et al. 2011; moors et al. 2009), and 
inhibition of precursor cell migration in the nervous system 
may lead to persistent and externally visible DT. If a DnT 
assay is designed to identify such effects, its validity esti-
mate would increase, as soon as it can be shown that the test 
is based on cell biological and signaling processes control-
ling precursor cell migration. validity would increase even 
more, if it can be demonstrated that compounds interfering 
with such processes are identified as hits in the test system. 
Furthermore, it would be important for mechanistic vali-
dation to demonstrate that chemicals score as hits because 
they interrupt such defined processes, and that toxicity may 
be rescued by a defined, mechanistically understood coun-
ter-regulation (Krug et al. 2013a; Zimmer et al. 2011b; Poltl 
et al. 2012; Wang et al. 2007; volbracht et al. 1999; Wayman 
et al. 2012a, b; schildknecht et al. 2013). The evaluation of 
such a test system would thereby be independent of classi-
cal positive controls; it would solely be based on knowledge 
regarding toxicity pathways. Our test battery framework 
would allow such approaches under the following condi-
tions: first, the same compounds will be tested in different, 
mechanistically defined test systems; by evaluating differ-
ent endpoints and comparing the data obtained from differ-
ent assays, more information will be gained on the general 
mode of action of those toxicants. The testing strategy needs 
to reach beyond the primary screening of toxicants to docu-
ment adverse effects; additional mechanistic characteriza-
tion in secondary assays and whole-genome transcriptom-
ics analysis of hits is an essential part of the strategy. This 
should promote our understanding of the pathways mainly 
affected by the exposure to the toxicants and of the path-
ways responsible for the toxicity.
Apart from the compound selection, we took a second 
unconventional approach with respect to the choice of com-
pound test concentrations. In drug discovery, it has been 
general practice to screen compounds at fixed absolute con-
centrations. In contrast to this, we used relative concentra-
tions. Biological activity of the compounds in vitro and in 
vivo, e.g., cytotoxicity, and clinical plasma concentrations 
were included as reference. Testing was performed relative 
to such reference concentrations. In most cases, the non-
cytotoxic range was evaluated and chosen as starting point 
for the screen. However, depending on the compounds, 
other criteria have been considered as more appropriate; 
this has been the case for cytokines that were tested in con-
centration ranges corresponding to the levels expected in 
body fluids during clinical application. This strategy was 
designed for test systems whose throughput is limited to 
some extent. For assays with very high throughput, an alter-
native approach would be to simply screen a large number 
of concentrations over the entire range of compound solu-
bility. This approach is taken for instance by the national 
toxicology program of the UsA (Xia et al. 2008; Attene-
ramos et al. 2013; Tice et al. 2013) or the ePA ToxCast 
program (Judson et al. 2010; sipes et al. 2013).
The current data are only derived from a first screening 
step. In the future one could imagine linking the functional 
disturbance of substances found in the mInC with more 
mechanistic data obtained in the assay itself, but also in other 
tests within the framework. This would allow to deepen our 
understanding of possible pathways of toxicity. Using the 
mInC assay in the first initial screen allowed us to identify 
23 % of compounds belonging to the drug group as potential 
DnT/DT toxicants. On the other hand, more than 70 % of the 
drugs in our library did not show any specific effect, although 
they have potent biological activity in many other tests. This 
suggests that the mInC assay does not react entirely unspe-
cifically to any drug-like compound or biologic.
Among the newly identified hits, we found three anti-
cancer drugs (abiraterone, geldanamycin and imatinib), 
an anti-psychotic drug (chlorpromazine) and a cytokine, 
mostly used for multiple sclerosis treatment (IFn-β). Abi-
raterone and imatinib have been shown to promote remis-
sion of different metastatic cancers (Patel 2013). Possibly, 
such findings are related to an inhibition of migration of 
cancer cells as well, and this may be tested in the future. 
Also in the case of the HsP90 inhibitor geldanamycin, 
other studies agree with our findings in the mInC assay. 
The effect of the drug on cell migration has been studied in 
several cancer cell lines. Activity of focal adhesion kinases, 
actin reorganization and integrin activation was inhibited 
by geldanamycin in bladder carcinoma cells (Koga et al. 
2007). Furthermore, chemotactic activity in sarcoma cells 
(Lesko et al. 2007) as well as migration of glioma cells was 
reduced (Zagzag et al. 2003). Also the dopamine antagonist 
chlorpromazine, has been shown by other studies to inhibit 
migration in a pancreatic carcinoma cell line, via inhibition 
of k-rAs (eisenberg et al. 2008).
Interference of IFn-β with migration has also been 
shown in several in vitro studies; the cytokine seems to 
modulate the activity of chemokine receptors and matrix 
remodeling proteases (e.g., CCr7, mmP9) in dendritic and 
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immune cells (yen et al. 2010; stuve et al. 1996). so far, 
these mechanistic findings have not been corroborated in an 
in vivo setting, but the drug showed potential DnT activ-
ity in in vivo studies (Us FDA, see materials and meth-
ods). modeling the pharmacokinetics of the drug, we found 
that the toxic effect is triggered by a blood concentration 
of 1.9–3 pm. About 100-fold higher concentrations may be 
reached upon bolus injections (i.v.) (yung et al. 1991), and 
the LOAeC observed in the mInC assay is about in the 
middle of this concentration range. The molecular targets 
responsible for the adverse effect of IFn-β seen in those 
and in our study are not known. We hope that further char-
acterization of the compound in the mInC assay and other 
assays of the battery will provide more details regarding 
the mode of action relevant for toxicity.
For the future, we suggest that the compound library 
may be expanded, and data from different publications and 
laboratories may be stored in a common database. It can-
not be stressed enough that initial hit-finding is only the 
first step of this strategy. Complementary information from 
multiple assays, pharmacokinetic modeling and mechanis-
tic follow-up studies are necessary components of the over-
all framework. For instance, transcriptome data and meas-
urement of other Omics and functional endpoints (Bouhifd 
et al. 2013; Hogberg et al. 2011; ramirez et al. 2013; 
Lefew et al. 2013) will expand our knowledge regarding 
the toxicity mechanisms of chemicals. moreover, such data 
will serve as a knowledge base concerning the biological 
processes and signaling pathways that need to be covered 
by a future DnT test battery. This will help us to identify 
redundancies, complementarities, strengths, weaknesses, 
applicability domains and limitations of current individual 
assays with regards to their predictive value for DnT.
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